#Hong Kong #Fangzhou Inc #Hang Seng #Biotech Index

Fangzhou Inc. Joins the Renowned Hang Seng Biotech Index

On December 3, 2024, Fangzhou Inc. officially announced its inclusion in the prestigious Hang Seng Hong Kong-Listed Biotech Index (HSHKBIO), effective December 9, 2024. This exciting development adds a significant chapter to the company's story as it continues to lead the way in Internet healthcare solutions.

As an integral player in the sector, Fangzhou has established a robust online platform that provides chronic disease management and personalized medical care. The company's shares, trading under the stock code 06086.HK on The Stock Exchange of Hong Kong Limited (HKEX), will now gain enhanced visibility among investors and stakeholders, thereby increasing opportunities for growth and collaboration.

Mr. Xie Fangmin, Chairman and CEO of Fangzhou, expressed enthusiasm regarding the inclusion, stating, "We are thrilled to be included in the Hang Seng Hong Kong-Listed Biotech Index. This recognition will elevate our profile among a broader spectrum of investors and create opportunities for our customers, partners, and investors to engage with our innovative Internet healthcare solutions."

About the Hang Seng Hong Kong-Listed Biotech Index

Established in 2019 by the Hang Seng Indexes Company Limited, the Hang Seng Hong Kong-Listed Biotech Index is designed to reflect the performance of biotech companies listed in Hong Kong. It comprises 50 of the largest companies within the biotechnology, pharmaceuticals, and medical devices sectors. Fangzhou's inclusion solidifies its position among industry leaders in a rapidly growing market.

With the rise of chronic diseases worldwide, Fangzhou is dedicated to enhancing healthcare accessibility and delivery. The company has been listed on the main board of HKEX since July 2024 and continues to expand its services in precision medicine and tailored medical care, driven by a user base of over 45.6 million registered users and a network of 217,000 registered doctors as of mid-2024.

Enhancing Healthcare Access

The biotechnology sector has been a focal point in advancing healthcare solutions, particularly in the management of chronic diseases. Fangzhou aims to leverage its inclusion in the HSHKBIO to strengthen its role as a pioneer in Internet healthcare and to foster partnerships that align with its vision for a healthier future.

This move not only enhances Fangzhou's visibility but also emphasizes its commitment to innovation in healthcare technology. The company is well-positioned to catalyze transformation in healthcare delivery through a blend of cutting-edge technology and personalized patient care.

In the coming months, Fangzhou plans to engage more deeply with the investor community and strengthen its collaborations within the healthcare ecosystem. As it continues to forge paths in Internet healthcare solutions, Fangzhou Inc. remains dedicated to improving the quality of life for patients dealing with chronic conditions.

In conclusion, Fangzhou Inc.'s inclusion in the Hang Seng Hong Kong-Listed Biotech Index marks a pivotal moment for the company, positioning it favorably for future growth and innovation in the global healthcare landscape. With ongoing enhancements to their service offerings and a commitment to accessibility, Fangzhou is set to play a crucial role in the future of healthcare.